Galeterone for Prostate Cancer
What is Galeterone?
Galeterone is a novel agent for the treatment of prostate cancer. It has some similarity to other agents including Xtandi and Zytiga but has additional features that suggest that it may be even more effective.
The following studies are on-going:
- ARMOR (Androgen Receptor Modulation Optimized for Response) is a study of galeterone (TOK-001) in patients with castration-resistant prostate cancer (CRPC).
- ARMOR3-SV: A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC (ARMOR3-SV)
Galeterone is being studied in patients with high-risk prostate cancer without metastatic disease; patients with metastatic disease who have not received hormonal therapy; patients who have failed on Zytiga and Xtandi.
Galeterone pharmacodynamics is not affected by diet, and therefore can be taken with or without food.
Galeterone works through a number of different mechanisms that are active in patients with CRPC. The goal is to block Athe R-dependent proliferation of prostate cancer cells. Examples include:
- Decreasing the production of androgen precursors within the adrenal gland and androgens within the tumor by inhibiting CYP17A1.
- Blocking the binding of androgens to the AR thereby blocking AAR-dependent signaling of tumor cell growth.
- Reducing the amount of AR protein within the tumor cells thereby reducing the sensitivity of tumors to androgens.
Galeterone also acts to degrade AR protein.
ARMOR3-SV trial is a study of the effectiveness of galeterone in patients who are not expected to respond to Xtandi or Zytiga due to expression of Androgen Receptor Splice Variant-7 mRNA (AR-V7) in Metastatic CRPC